Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Non Operating Income: 2017-2025

Historic Non Operating Income for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $2.5 million.

  • Aclaris Therapeutics' Non Operating Income fell 12.13% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 30.27%. This contributed to the annual value of $9.9 million for FY2024, which is 15.96% up from last year.
  • Aclaris Therapeutics' Non Operating Income amounted to $2.5 million in Q3 2025, which was down 14.90% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Non Operating Income ranged from a high of $3.1 million in Q4 2024 and a low of -$851,000 during Q3 2021.
  • Moreover, its 3-year median value for Non Operating Income was $2.3 million (2023), whereas its average is $2.4 million.
  • Per our database at Business Quant, Aclaris Therapeutics' Non Operating Income crashed by 338.66% in 2021 and then surged by 1,522.47% in 2022.
  • Over the past 5 years, Aclaris Therapeutics' Non Operating Income (Quarterly) stood at $89,000 in 2021, then surged by 1,522.47% to $1.4 million in 2022, then skyrocketed by 51.59% to $2.2 million in 2023, then skyrocketed by 42.67% to $3.1 million in 2024, then decreased by 12.13% to $2.5 million in 2025.
  • Its Non Operating Income stands at $2.5 million for Q3 2025, versus $3.0 million for Q2 2025 and $3.0 million for Q1 2025.